Stages III-IV Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01-23-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (06-28-2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (06-6-2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (01-4-2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing... Continue Reading

Lynparza Improves Overall Survival in High-Risk Gastric Cancer (09-9-2015)

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (08-10-2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

Reolysin® Receives FDA Designation for Gastric Cancer (05-14-2015)

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc. recently announced the designation in a press release. The... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (02-20-2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (02-12-2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (11-13-2014)

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved... Continue Reading

Next Page »